Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Texas Southwestern Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Rochester
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Icahn School of Medicine at Mount Sinai
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Vanderbilt University Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Memorial Sloan Kettering Cancer Center
Istituto Oncologico Veneto IRCCS
West China Hospital
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center